ALZN - Alzamend Neuro

-

$undefined

N/A

(N/A)

Alzamend Neuro NasdaqCM:ALZN Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Location: 3480 Peachtree Road NE, Suite C112c, Atlanta, GA, 30326, United States | Website: https://www.alzamend.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

629.7K

Cash

3.358M

Avg Qtr Burn

-1.827M

Short % of Float

20.29%

Insider Ownership

3.22%

Institutional Own.

0.88%

Qtr Updated

01/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
AL001 Details
Alzheimer's disease

Phase 2

Data readout

AL001 Details
Healthy Subjects (Baseline Study)

Phase 2

Data readout

AL001 Details
Major depressive disorder

Phase 2

Initiation

AL001 Details
Post-traumatic stress disorder

Phase 2

Initiation

AL001 Details
Bipolar disease

Phase 2

Initiation

ALZN002 Details
Alzheimer's disease, Dementia

Phase 1/2

Data readout